EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
暂无分享,去创建一个
Thomas Wiegel | Joaquim Bellmunt | Michel Bolla | Nicolas Mottet | Steven Joniau | Theo van der Kwast | T. H. van der Kwast | T. Wiegel | M. Bolla | M. Mason | H. Schmid | V. Matveev | J. Bellmunt | A. Heidenreich | S. Joniau | N. Mottet | Hans-Peter Schmid | Axel Heidenreich | Vsevolod Matveev | F. Zattoni | Filliberto Zattoni | Malcolm Mason
[1] I. Tsaur,et al. Active surveillance , 2020, Ureteroceles.
[2] T. Johansson,et al. Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15]. , 2011, European urology.
[3] A. Kibel. Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95 , 2010 .
[4] Tim Johansson,et al. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. , 2010, European urology.
[5] A. Haese*,et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? , 2010, BJU international.
[6] A. Haese*,et al. Follow‐up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? , 2010, BJU international.
[7] A. Partin,et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. , 2010, Urology.
[8] L. Klotz,et al. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. , 2010, The Journal of urology.
[9] M. Sydes,et al. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] V. Molinie,et al. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer. , 2010 .
[11] L. Klotz. Active Surveillance for Prostate Cancer: A Review , 2010, Current urology reports.
[12] K. Wallner,et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.
[13] U. Capitanio,et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. , 2010, European urology.
[14] Andrzej Niemierko,et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. , 2010, JAMA.
[15] J. Ferlay,et al. Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.
[16] H. Rübben,et al. Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom , 2010, Der Urologe.
[17] B. Donnelly,et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer , 2010, Cancer.
[18] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[19] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[20] B. Donnelly,et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer , 2009, Cancer.
[21] K. Trpkov,et al. No residual cancer on radical prostatectomy after positive 10-core biopsy: incidence, biopsy findings, and DNA specimen identity analysis. , 2009, Archives of pathology & laboratory medicine.
[22] J. Srigley,et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. , 2009, The Journal of urology.
[23] Andrew J Vickers,et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Willich,et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Messing,et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. , 2009, The Journal of urology.
[26] T. Wilt,et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. , 2009, Cancer treatment reviews.
[27] Michel Bolla,et al. [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.
[28] S. Fosså,et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.
[29] Andrew J Vickers,et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Catalona,et al. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? , 2009, Nature Clinical Practice Urology.
[31] John G Baust,et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. , 2008, The Journal of urology.
[32] J. Chin,et al. UPDATE OF SWOG 8794: ADJUVANT RADIOTHERAPY FOR PT3 PROSTATE CANCER IMPROVES METASTASIS FREE SURVIVAL , 2008 .
[33] L. Holmberg,et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.
[34] F. Fazio,et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. , 2008, European urology.
[35] L. Bégin,et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance , 2008, Cancer.
[36] Y. Kitagawa,et al. Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion , 2008, International Journal of Clinical Oncology.
[37] Yoshiya Yamada,et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.
[38] L. Collette,et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). , 2008, European urology.
[39] L. Ferrucci,et al. Prostate specific antigen testing among the elderly--when to stop? , 2008, The Journal of urology.
[40] Seongjoon Koo,et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.
[41] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[42] D. Pfister,et al. Percentage of positive biopsies predicts lymph node involvement in men with low‐risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy , 2008, BJU international.
[43] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[44] Y. Jo,et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. , 2008, Urology.
[45] S. Joniau,et al. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. , 2008, European urology.
[46] R. Miralbell,et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[47] A. Renshaw,et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.
[48] Sylvie Chabaud,et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] P. Scardino,et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.
[50] W. Catalona,et al. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. , 2007, Urology.
[51] M. Beheshti,et al. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[52] K. Haustermans,et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. , 2007, European urology.
[53] T. Wilt,et al. Screening for prostate cancer: A Cochrane systematic review , 2007, Cancer Causes & Control.
[54] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] T. Wilt,et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.
[56] F. Montorsi,et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.
[57] Yoshiya Yamada,et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.
[58] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[59] Susanne Hempel,et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. , 2006, The Journal of urology.
[60] Joos V Lebesque,et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] L. Collette,et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] V. Kundra. Prostate cancer imaging. , 2006, Seminars in roentgenology.
[63] M. Wirth,et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer , 2006, BJU international.
[64] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[65] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[66] M. Piérart,et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.
[67] R. Clayman. Celecoxib inhibits ureteral contractility and prostanoid release. , 2005, The Journal of urology.
[68] E. Bergstralh,et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome , 2005, BJU international.
[69] K. Stravodimos,et al. Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream , 2004, World Journal of Urology.
[70] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[71] D. Kuban,et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. , 2003, International journal of radiation oncology, biology, physics.
[72] T. H. van der Kwast,et al. Guidelines for processing and reporting of prostatic needle biopsies , 2003, Journal of clinical pathology.
[73] O. Bratt. Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.
[74] A. Heidenreich,et al. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.
[75] In the News: Compiled from Agency for Healthcare Research and Quality Web Site , 2001, The Journal of Perinatal Education.
[76] D. Ash,et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[77] M. Aron,et al. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study , 2000, BJU international.
[78] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[79] J. Hanley,et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.
[80] W. Catalona,et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. , 1999, The Journal of urology.
[81] D. Carter. TNM Classification of Malignant Tumors , 1998 .
[82] P. Walsh. Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.
[83] Alexandre Mamedov,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] R. Dhir. Prostate Specific Antigen Testing Among the Elderly–When To Stop? , 2010 .
[85] M. Graefen,et al. [Problems, objective, and substance of early detection of prostate cancer]. , 2010, Der Urologe. Ausg. A.
[86] A. Gavin,et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. , 2010, European journal of cancer.
[87] C. Lawton. Duration of Androgen Suppression in the Treatment of Prostate Cancer , 2010 .
[88] A. Prando. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program , 2010 .
[89] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[90] C. Stephan,et al. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? , 2009, Clinical chemistry and laboratory medicine.
[91] S. Freedland,et al. Role of androgen deprivation therapy for node-positive prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] Y. Jo,et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy , 2008, Prostate Cancer and Prostatic Diseases.
[93] R. Laing,et al. State-of-the-art: prostate LDR brachytherapy , 2008, Prostate Cancer and Prostatic Diseases.
[94] Michael W Kattan,et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. , 2007, Radiology.
[95] M. Marberger. Postoperative Radiotherapy After Radical Prostatectomy: A Randomized Controlled Trial (EORTC trial 22911) , 2006 .
[96] R. Kuefer,et al. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. , 2004, European urology.
[97] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[98] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.